Search Result

Results for "

delta opioid receptors

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Opioid Receptor (146) 5-HT Receptor (1) Akt (5) Amino Acid Derivatives (1) Aminopeptidase (3) Androgen Receptor (2) Angiotensin-converting Enzyme (ACE) (1) Apoptosis (2) Arrestin (3) Beta-secretase (1) Caspase (2) Cytochrome P450 (2) Dopamine Receptor (1) Drug Derivative (1) Drug Intermediate (1) Drug Metabolite (5) Endogenous Metabolite (4) Enteropeptidase (2) ERK (3) Flavivirus (1) Fluorescent Dye (1) GABA Receptor (2) iGluR (5) Interleukin Related (1) Isotope-Labeled Compounds (6) Leukotriene Receptor (1) mAChR (5) Mas-related G-protein-coupled Receptor (MRGPR) (1) MMP (5) mTOR (2) NF-κB (6) Orexin Receptor (OX Receptor) (1) PI3K (5) Potassium Channel (2) Prolyl Endopeptidase (PREP) (1) Reference Standards (11) Sigma Receptor (1) TNF Receptor (2) TRP Channel (2) Virus Protease (4)
By Research Areas:	Cancer (12) Cardiovascular Disease (1) Endocrinology (1) Infection (5) Inflammation/Immunology (24) Metabolic Disease (9) Neurological Disease (132)

By Targets:

Opioid Receptor (146)

5-HT Receptor (1)

Akt (5)

Amino Acid Derivatives (1)

Aminopeptidase (3)

Androgen Receptor (2)

Angiotensin-converting Enzyme (ACE) (1)

Apoptosis (2)

Arrestin (3)

Beta-secretase (1)

Caspase (2)

Cytochrome P450 (2)

Dopamine Receptor (1)

Drug Derivative (1)

Drug Intermediate (1)

Drug Metabolite (5)

Endogenous Metabolite (4)

Enteropeptidase (2)

ERK (3)

Flavivirus (1)

Fluorescent Dye (1)

GABA Receptor (2)

iGluR (5)

Interleukin Related (1)

Isotope-Labeled Compounds (6)

Leukotriene Receptor (1)

mAChR (5)

Mas-related G-protein-coupled Receptor (MRGPR) (1)

MMP (5)

mTOR (2)

NF-κB (6)

Orexin Receptor (OX Receptor) (1)

PI3K (5)

Potassium Channel (2)

Prolyl Endopeptidase (PREP) (1)

Reference Standards (11)

Sigma Receptor (1)

TNF Receptor (2)

TRP Channel (2)

Virus Protease (4)

By Research Areas:

Cancer (12)

Cardiovascular Disease (1)

Endocrinology (1)

Infection (5)

Inflammation/Immunology (24)

Metabolic Disease (9)

Neurological Disease (132)

156

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: Opioid Receptor

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-76711

Naltrexone	Opioid Receptor	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Naltrexone is an orally active, long-acting opioid receptor (opioid *receptor) antagonist. Naltrexone blocks the euphoric effects of exogenous opioids* and reduces alcohol craving by blocking opioid receptors (μ, κ, and δ) as well as opioid growth factor receptors. Low doses of Naltrexone are used to relieve chronic pain, treat inflammatory diseases and inhibit tumor growth, while high doses or continuous administration exert pro-inflammatory or pro-proliferative effects. Naltrexone relieves intractable pruritus caused by psoriasis, atopic dermatitis and other conditions, and its combination with Bupropion (HY-B0403) inhibits food craving, thereby reducing body weight .

HY-P1502

β-Endorphin, human 1 Publications Verification	Opioid Receptor	Neurological Disease
β-Endorphin, human, a prominent endogenous peptide, existing in the hypophysis cerebri and hypothalamus, is an agonist of **opioid receptor*, with preferred affinity for μ-opioid* receptor and δ-opioid receptor; β-Endorphin, human exhibits antinociception activity.

HY-P1333

Dynorphin A 1 Publications Verification	Opioid Receptor Apoptosis Caspase Endogenous Metabolite	Neurological Disease
Dynorphin A is an endogenous opioid peptide involved in inhibitory neurotransmission in the central nervous system (CNS). Dynorphin A is a highy potent *kappa opioid* receptor (KOR)** agonist, and is also an agonist for other opioid receptors, such as mu (MOR) and delta (DOR). Dynorphin A can induce neuronal death, and can be used in the research of neurological disease .

HY-13243

Alvimopan 2 Publications Verification ADL 8-2698; LY 246736	Opioid Receptor	Neurological Disease
Alvimopan (ADL 8-2698) is a potent, selective, orally active and reversible μ-opioid receptor antagonist, with an IC₅₀ of 1.7 nM. Alvimopan has selectivity for μ-opioid receptor (K_i=0.47 nM) over κ- and δ-opioid receptors (K_is=100, 12 nM, respectively). Alvimopan can be used for the research of postoperative ileus .

HY-101302

Naltriben mesylate 2 Publications Verification	Opioid Receptor TRP Channel	Inflammation/Immunology
Naltriben mesylate is a potent δ2-opioid receptor antagonist and a TRPM7 activator. Naltriben mesylate shows K_i values of 0.013 nM, 19 nM and 152 nM for δ, μ and κ receptors, respectively. Naltriben mesylate enhances glioblastoma cell migration and invasion. Naltriben mesylate can be used in research into neurological diseases and cancer .

HY-P1335

CTAP 2 Publications Verification	Opioid Receptor	Neurological Disease
CTAP is a potent, highly selective, and BBB penetrant μ opioid receptor antagonist, with an IC₅₀ of 3.5 nM. CTAP displays over 1200-fold selectivity over δ opioid (IC₅₀=4500 nM) and somatostatin receptors. CTAP can be used for the study of L-DOPA-induced dyskinesia (LID) and opiate overdose or addiction .

HY-P1334

DPDPE 1 Publications Verification	Opioid Receptor	Neurological Disease
DPDPE, an opioid peptide, is a selective δ-opioid receptor?(DOR) agonist?with anticonvulsant effects .

HY-123689

Samidorphan ALKS-33; RDC-0313	Opioid Receptor	Neurological Disease
Samidorphan (ALKS-33) is an orally active *opioid* system modulator that has a high affinity for binding with μ‐opioid, κ‐opioid, and δ‐opioid receptors. Samidorphan acts as an antagonist at μ‐opioid receptors and acts as a partial agonist at k-opioid and δ‐opioid receptors. Samidorphan primarily acts as an opioid receptor antagonist in vivo. Samidorphan can improve the behavior of depressed animals .

HY-P0098

[D-Ala2]leucine-enkephalin	Opioid Receptor	Neurological Disease Inflammation/Immunology
[D-Ala2]leucine-enkephalin, a **delta opioid** agonist, is a degradation resistant long-acting Leu-enkephalin analog used to study the signaling pathway of delta opioid receptors.

HY-P1470

[Leu5]-Enkephalin, amide Leu-Enkephalin amide	Opioid Receptor	Neurological Disease
[Leu5]-Enkephalin, amide is a δ opioid receptor agonist.

HY-P1336

Deltorphin I Deltorphin 1; Deltorphin C; [D-Ala2] Deltorphin I	Opioid Receptor	Neurological Disease
Deltorphin I is a δ-opioid receptor agonist with high affinity and selectivity.

HY-104006

CYM51010	Opioid Receptor	Neurological Disease
CYM51010 is a biased ligand of μ-opioid receptor – δ-opioid receptor heterodimers with an EC₅₀ of 403 nM. CYM51010 exhibits anti-nociceptive activity similar to morphine but with a decreased levels of tolerance development and withdrawal symptoms .

HY-107741

SNC162	Opioid Receptor	Neurological Disease
SNC162 is a **delta-opioid receptor agonist with an IC₅₀** of 0.94 nM. SNC162 has antidepressant-like and antinociceptiv effects .

HY-76711S

Naltrexone-d4	Isotope-Labeled Compounds Opioid Receptor	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Naltrexone-d4 is deuterium labeled Naltrexone (HY-76711). Naltrexone is an orally active, long-acting opioid receptor (opioid *receptor) antagonist. Naltrexone blocks the euphoric effects of exogenous opioids* and reduces alcohol craving by blocking opioid receptors (μ, κ, and δ) as well as opioid growth factor receptors. Low doses of Naltrexone are used to relieve chronic pain, treat inflammatory diseases and inhibit tumor growth, while high doses or continuous administration exert pro-inflammatory or pro-proliferative effects. Naltrexone relieves intractable pruritus caused by psoriasis, atopic dermatitis and other conditions, and its combination with Bupropion (HY-B0403) inhibits food craving, thereby reducing body weight.

HY-P1467A

[Met5]-Enkephalin, amide TFA 5-Methionine-enkephalin amide TFA	Opioid Receptor	Neurological Disease
[Met5]-Enkephalin, amide TFA is an agonist for δ opioid receptors as well as putative ζ ζ opioid receptors.

HY-P1334A

DPDPE TFA 1 Publications Verification	Opioid Receptor	Neurological Disease
DPDPE TFA, an opioid peptide, is a selective δ-opioid receptor (DOR) agonist with anticonvulsant effects .

HY-14157

ADL-5747	Opioid Receptor	Inflammation/Immunology
ADL-5747 is a selective and orally active agonist of the δ-opioid receptor (DOR). By binding to the δ-opioid receptors, ADL-5747 activates these receptors, thereby playing a role in pain management pathways. ADL-5747 can be used for research into pain management mechanisms .

HY-P1013A

Deltorphin 2 TFA 3 Publications Verification [D-Ala2]-Deltorphin II TFA	Opioid Receptor	Neurological Disease
Deltorphin 2 TFA is a selective peptide agonist for the δ opioid receptor .

HY-137279

Naloxone methiodide 1 Publications Verification	Opioid Receptor	Inflammation/Immunology
Naloxone methiodide is a peripherally restricted, nonselective, and competitive opioid receptor antagonist. Naloxone methiodide does not penetrate the blood-brain barrier .

HY-W048697

Fmoc-D-Pen(Trt)-OH	Amino Acid Derivatives	Others
Fmoc-D-Pen(Trt)-OH is an amino acid derivative with an Fmoc protecting group, which can be used to synthesize analogs of cyclic lanthionine enkephalin, a δ-opioid receptor selective ligand .

HY-P1335A

CTAP TFA 2 Publications Verification	Opioid Receptor	Neurological Disease
CTAP TFA is a potent, highly selective, and BBB penetrant μ opioid receptor antagonist, with an IC₅₀ of 3.5 nM. CTAP TFA displays over 1200-fold selectivity over δ opioid (IC₅₀=4500 nM) and somatostatin receptors. CTAP TFA can be used for the study of L-DOPA-induced dyskinesia (LID) and opiate overdose or addiction .

HY-136208

TAN-452	Opioid Receptor	Neurological Disease
TAN-452 is an orally active, selective peripherally acting *δ-opioid* receptor (DOR) antagonist with a K_i of 0.47 nM and a K_b** of 0.21 nM. TAN-452 is an antagonist for μ-opioid receptor (MOR; K_i=36.56 nM and K_b=9.43 nM) and κ-opioid receptor (KOR; K_i=5.31 nM and K_b=7.18 nM). TAN-452, a derivative of Naltrindole, demonstrates low brain penetrability and attenuates morphine-induced side effects without affecting pain control .

HY-101307

BNTX maleate 7-Benzylidenenaltrexone maleate	Opioid Receptor	Neurological Disease
BNTX (7-Benzylidenenaltrexone) maleate is a *δ1-opioid* receptor antagonist with the K_is of 0.1, 10.8, 13.3, and 58.6 nM for δ1, δ2-, μ-, and κ-opioid receptor, respectively. BNTX maleate shows antinociceptive activity .

HY-101230

ICI 174864	Opioid Receptor	Neurological Disease
ICI 174864 is a selective and brain-penetrant δ-opioid receptor antagonist with K_e values of 22.0 nM to 30.6 nM at δ-opioid receptor in mouse vas deferens. ICI 174864 selectively blocks biological effects mediated by the δ-opioid receptor agonist DPDPE (HY-P1334) after central administration. ICI 174864 reverses hypotension in rats with endotoxic shock and inhibits acetic acid-induced writhing in mice. ICI 174864 can be used for the research of opioid receptor subtypes, endotoxic hypotension and analgesic pathways .

HY-107750A

Cyprodime hydrochloride	Opioid Receptor	Neurological Disease
Cyprodime hydrochloride is a highly selective μ-opioid receptor antagonist with K_i values of 5.4 nM, 244.6 nM and 2187 nM for μ-, δ- and κ-opioid receptors, respectively. Cyprodime hydrochloride has anti-depressant-like effect .

HY-P1866A

β-Endorphin, equine TFA 1 Publications Verification	Opioid Receptor	Neurological Disease
β-Endorphin, equine TFA is an endogenous opioid peptide, which binds at high affinity to both μ/δ opioid receptors. β-Endorphin, equine TFA has analgesic properties .

HY-76657A

Alvimopan dihydrate 2 Publications Verification ADL 8-2698 dihydrate; LY 246736 dihydrate	Opioid Receptor	Neurological Disease Cancer
Alvimopan dihydrate (ADL 8-2698 dihydrate) is a potent, selective, orally active and reversible μ-opioid receptor antagonist, with an IC₅₀ of 1.7 nM. Alvimopan dihydrate has selectivity for μ-opioid receptor (K_i=0.47 nM) over κ- and δ-opioid receptors (K_is=100, 12 nM, respectively). Alvimopan dihydrate can be used for the research of postoperative ileus .

HY-P3546

[DPen2, Pen5] Enkephalin	Opioid Receptor	Neurological Disease
[DPen2, Pen5] Enkephalin is a δ-opioid receptor selective analog of [Leu5]-Enkephalin (HY-P0288) .

HY-76711R

Naltrexone (Standard)	Reference Standards Opioid Receptor	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Naltrexone (Standard) is the analytical standard of Naltrexone (HY-76711). This product is intended for research and analytical applications. Naltrexone is an orally active, long-acting opioid receptor (opioid *receptor) antagonist. Naltrexone blocks the euphoric effects of exogenous opioids* and reduces alcohol craving by blocking opioid receptors (μ, κ, and δ) as well as opioid growth factor receptors. Low doses of Naltrexone are used to relieve chronic pain, treat inflammatory diseases and inhibit tumor growth, while high doses or continuous administration exert pro-inflammatory or pro-proliferative effects. Naltrexone relieves intractable pruritus caused by psoriasis, atopic dermatitis and other conditions, and its combination with Bupropion (HY-B0403) inhibits food craving, thereby reducing body weight.

HY-169867

BNTX 7-Benzylidenenaltrexone	Opioid Receptor	Neurological Disease
BNTX (7-Benzylidenenaltrexone) is a highly selective δ1 opioid receptor antagonist. BNTX selectively antagonizes the antinociceptive activity mediated by spinal δ₁ opioid receptors, and does not alter the antinociceptive effects mediated by δ₂, μ or κ opioid receptors at selective doses .

HY-P1013

Deltorphin 2 [D-Ala2]-Deltorphin II	Opioid Receptor	Neurological Disease
Deltorphin 2 is a selective peptide agonist for the δ opioid receptor.

HY-101039A

AR-M 1000390 hydrochloride	Opioid Receptor	Neurological Disease
AR-M 1000390 hydrochloride is an exceptionally selective, potent δ opioid receptor agonist with an EC₅₀ of 7.2±0.9 nM for δ agonist potency.

HY-107743

Naloxone benzoylhydrazone NalBzoH	Opioid Receptor	Neurological Disease
Naloxone benzoylhydrazone (NalBzoH) is a mixed agonist/antagonist. Naloxone benzoylhydrazone is a prototypic κ3-opioid receptor agonist, and a partial agonist at the cloned μ and δ opioid receptors, and an antagonist at **opioid-like NOP receptors**. Naloxone benzoylhydrazone has potently analgesia effect .

HY-101233

ICI 154129 M 154129	Opioid Receptor	Neurological Disease
ICI 154 129 is a **delta-opioid receptor** antagonist and can be used for seizure research.

HY-P3555

D-Ala-Gly-Phe-Met-NH2	Opioid Receptor	Others
D-Ala-Gly-Phe-Met-NH2, an opioid peptide, is a potent opiate δ-receptor agonist .

HY-19231

DPI-3290 Org 41793	Opioid Receptor	Neurological Disease
DPI-3290 (Org 41793) is a potent and specific **opioid receptors agonist with K_i** values of 0.18 nM, 0.46 nM, and 0.62 nM for δ-, μ-, and κ-opioid receptors, respectively. DPI-3290 is one of a series of novel centrally acting agents with potent antinociceptive activity .

HY-178235

MDAN-21	Opioid Receptor	Neurological Disease
MDAN-21 is a bivalent opioid ligand that contains both μ-opioid receptor agonists and δ-opioid receptor antagonists. MDAN-21 has a strong analgesic effect and does not produce tolerance in mouse studies. MDAN-21 can effectively inhibit the withdrawal of morphine dependent monkeys and alleviate abnormal pain in the study of rhesus monkeys. MDAN-21 can be used for the study of allodynia .

HY-A0115R

Ramiprilat (Standard) HOE 498 diacid (Standard); Ramipril diacid (Standard)	Drug Metabolite Reference Standards Angiotensin-converting Enzyme (ACE) Endogenous Metabolite	Cardiovascular Disease
Alvimopan (dihydrate) (Standard) is the analytical standard of Alvimopan (dihydrate). This product is intended for research and analytical applications. Alvimopan dihydrate (ADL 8-2698 dihydrate) is a potent, selective, orally active and reversible μ-opioid receptor antagonist, with an IC50 of 1.7 nM. Alvimopan dihydrate has selectivity for μ-opioid receptor (Ki=0.47 nM) over κ- and δ-opioid receptors (Kis=100, 12 nM, respectively). Alvimopan dihydrate can be used for the research of postoperative ileus .

HY-16979

TRK-851	Opioid Receptor	Neurological Disease
RK-851 is a highly selective and orally active δ-opioid receptor antagonist, with a negative logarithm of the antagonist concentration (pA₂) of 8.84. TRK-851 exhibits the selectivity for the δ receptor of more than 100 times higher than that for the μ or κ receptors. TRK-851 exhibits a potent antitussive effect in a rat model of capsaicin-induced cough. TRK-851 can be used for research on antitussive effects .

HY-175661

SRI-22136	Opioid Receptor Beta-secretase	Neurological Disease
SRI-22136 is a Delta Opioid Receptor (DOR) antagonist that can cross blood-brain barrier with a IC₅₀ of 0.42 nM. SRI-22136 does not have agonistic activity but antagonistic activity against DOR, MOR (IC₅₀ = 370 nM), KOR (IC₅₀ = 54 nM) and can avoid addiction/aversion effects. SRI-22136 can effectively inhibit the BACE1 activity induced by DADLE (a DOR agonist) (HY-105343) (IC₅₀ = 120 nM). SRI-22136 prevents completely Alzheimer’s-like pathology in mouse model. SRI-22136 can used for the study of Alzheimer’s disease .

HY-123689S1

Samidorphan-d5 ALKS-33-d₅; RDC-0313-d₅	Isotope-Labeled Compounds Opioid Receptor	Neurological Disease
Samidorphan-d5 (ALKS-33-d5) is is a deuterated compound of Samidorphan. Samidorphan is an orally active *opioid* system modulator that binds with high affinity to *μ-opioid, κ-opioid, and δ-opioid* receptors. Samidorphan is a *μ-opioid* receptor antagonist and a partial agonist at *k-opioid* and *δ-opioid* receptors. Samidorphan acts primarily as an *opioid* receptor antagonist in vivo .

HY-P1467

[Met5]-Enkephalin, amide 5-Methionine-enkephalin amide	Opioid Receptor	Neurological Disease
[Met5]-Enkephalin, amide is an agonist for δ opioid receptors as well as putative ζ ζ opioid receptors.

HY-101317A

TAN-67 SB-205607	Opioid Receptor	Metabolic Disease
TAN-67 (SB-205607) is a non-peptidic delta-opioid receptor agonist that exhibits significant antinociceptive activity in both diabetic and non-diabetic mice. TAN-67 demonstrates a marked and dose-dependent reduction in acetic acid-induced abdominal constrictions, with a notably stronger effect in diabetic mice compared to their non-diabetic counterparts. TAN-67's antinociceptive properties are primarily mediated through the activation of delta 1-opioid receptors, as indicated by the pronounced antagonism observed upon administration of a selective delta 1-opioid receptor antagonist.

HY-133717

Naltriben	Opioid Receptor TRP Channel	Cancer
Naltriben is a selective δ2-opioid receptor antagonist and TRPM7 activator. Naltriben enhances glioblastoma cell migration and invasion. Naltriben can be used in research into neurological diseases and cancer .

HY-151811

NAQ	Opioid Receptor	Neurological Disease
NAQ is a potent and selective μ opioid receptor partial agonist, with a K_i of 0.55 nM. NAQ shows selectivity for Mu opioid receptor over the δ receptor (K_i=132.50 nM) and the κ receptor (K_i=26.45 nM). NAQ can be used for the research of opioid withdrawal or dependence .

HY-P1866

β-Endorphin, equine	Opioid Receptor	Neurological Disease
β-Endorphin, equine is an endogenous opioid peptide, which binds at high affinity to both μ/δ opioid receptors . Analgesic properties .

HY-P1332

DSLET [D-Ser2, Leu5, Thr6]-enkephalin	Opioid Receptor	Neurological Disease
DSLET ([D-Ser2, Leu5, Thr6]-enkephalin) is a highly specific agonist of the *δ-receptor. DSLET is an enkephalin-related peptide selectively bound to the δ opioid* receptor .

HY-120024

BMS-986188	Opioid Receptor	Neurological Disease
BMS-986188 is a selective positive allosteric modulator of δ-opioid receptor with an EC₅₀ of 0.05 μM .

HY-16765

Axelopran TD-1211	Opioid Receptor	Neurological Disease
Axelopran (TD-1211) is an opioid receptor antagonist with pKi values of 9.8, 8.8 and 9.9 for human recombinant μ and δ receptors and guinea pig κ receptor, respectively.

HY-106732

AT-076	Opioid Receptor	Neurological Disease
AT-076 is an opioid pan antagonist at nociception, kappa, mu, and **delta opioid** receptors, with K_i values of 1.75 nM (NOP), 1.67 nM (MOP), 1.14 nM (KOP) and 19.6 nM (DOP), respectively .

Cat. No.	Product Name	Target	Research Area

HY-P1502

β-Endorphin, human 1 Publications Verification	Opioid Receptor	Neurological Disease
β-Endorphin, human, a prominent endogenous peptide, existing in the hypophysis cerebri and hypothalamus, is an agonist of **opioid receptor*, with preferred affinity for μ-opioid* receptor and δ-opioid receptor; β-Endorphin, human exhibits antinociception activity.

HY-P1333

Dynorphin A 1 Publications Verification	Opioid Receptor Apoptosis Caspase Endogenous Metabolite	Neurological Disease
Dynorphin A is an endogenous opioid peptide involved in inhibitory neurotransmission in the central nervous system (CNS). Dynorphin A is a highy potent *kappa opioid* receptor (KOR)** agonist, and is also an agonist for other opioid receptors, such as mu (MOR) and delta (DOR). Dynorphin A can induce neuronal death, and can be used in the research of neurological disease .

HY-P1335

CTAP 2 Publications Verification	Opioid Receptor	Neurological Disease
CTAP is a potent, highly selective, and BBB penetrant μ opioid receptor antagonist, with an IC₅₀ of 3.5 nM. CTAP displays over 1200-fold selectivity over δ opioid (IC₅₀=4500 nM) and somatostatin receptors. CTAP can be used for the study of L-DOPA-induced dyskinesia (LID) and opiate overdose or addiction .

HY-P1334

DPDPE 1 Publications Verification	Opioid Receptor	Neurological Disease
DPDPE, an opioid peptide, is a selective δ-opioid receptor?(DOR) agonist?with anticonvulsant effects .

HY-P4053

Dalargin	Opioid Receptor	Neurological Disease
Dalargin is a potent δ-opioid receptor agonist. Dalargin mitigates Gentamicin (HY-A0276)-induced cell death. Dalargin shows nephroprotective effects on Gentamicin (HY-A0276A)-induced kidney injury. Dalargin shows antiulcer activity .

HY-P0098

[D-Ala2]leucine-enkephalin	Opioid Receptor	Neurological Disease Inflammation/Immunology
[D-Ala2]leucine-enkephalin, a **delta opioid** agonist, is a degradation resistant long-acting Leu-enkephalin analog used to study the signaling pathway of delta opioid receptors.

HY-P1470

[Leu5]-Enkephalin, amide Leu-Enkephalin amide	Opioid Receptor	Neurological Disease
[Leu5]-Enkephalin, amide is a δ opioid receptor agonist.

HY-P1336

Deltorphin I Deltorphin 1; Deltorphin C; [D-Ala2] Deltorphin I	Opioid Receptor	Neurological Disease
Deltorphin I is a δ-opioid receptor agonist with high affinity and selectivity.

HY-105343

BW-180C 1 Publications Verification [D-Ala2, D-Leu5]-Enkephalin; DADLE	Opioid Receptor	Neurological Disease
BW-180C ([D-Ala2, D-Leu5]-Enkephalin; DADLE) is an δ opioid receptor (DOR) agonist, which belongs to the enkephalin family. Neuroprotective agent. BW-180C reversibly inhibits cellular transcription in neurons without causing cell injury .

HY-P1467A

[Met5]-Enkephalin, amide TFA 5-Methionine-enkephalin amide TFA	Opioid Receptor	Neurological Disease
[Met5]-Enkephalin, amide TFA is an agonist for δ opioid receptors as well as putative ζ ζ opioid receptors.

HY-P1334A

DPDPE TFA 1 Publications Verification	Opioid Receptor	Neurological Disease
DPDPE TFA, an opioid peptide, is a selective δ-opioid receptor (DOR) agonist with anticonvulsant effects .

HY-P1013A

Deltorphin 2 TFA 3 Publications Verification [D-Ala2]-Deltorphin II TFA	Opioid Receptor	Neurological Disease
Deltorphin 2 TFA is a selective peptide agonist for the δ opioid receptor .

HY-W048697

Fmoc-D-Pen(Trt)-OH	Amino Acid Derivatives	Others
Fmoc-D-Pen(Trt)-OH is an amino acid derivative with an Fmoc protecting group, which can be used to synthesize analogs of cyclic lanthionine enkephalin, a δ-opioid receptor selective ligand .

HY-P1335A

CTAP TFA 2 Publications Verification	Opioid Receptor	Neurological Disease
CTAP TFA is a potent, highly selective, and BBB penetrant μ opioid receptor antagonist, with an IC₅₀ of 3.5 nM. CTAP TFA displays over 1200-fold selectivity over δ opioid (IC₅₀=4500 nM) and somatostatin receptors. CTAP TFA can be used for the study of L-DOPA-induced dyskinesia (LID) and opiate overdose or addiction .

HY-101230

ICI 174864	Opioid Receptor	Neurological Disease
ICI 174864 is a selective and brain-penetrant δ-opioid receptor antagonist with K_e values of 22.0 nM to 30.6 nM at δ-opioid receptor in mouse vas deferens. ICI 174864 selectively blocks biological effects mediated by the δ-opioid receptor agonist DPDPE (HY-P1334) after central administration. ICI 174864 reverses hypotension in rats with endotoxic shock and inhibits acetic acid-induced writhing in mice. ICI 174864 can be used for the research of opioid receptor subtypes, endotoxic hypotension and analgesic pathways .

HY-P1866A

β-Endorphin, equine TFA 1 Publications Verification	Opioid Receptor	Neurological Disease
β-Endorphin, equine TFA is an endogenous opioid peptide, which binds at high affinity to both μ/δ opioid receptors. β-Endorphin, equine TFA has analgesic properties .

HY-P3546

[DPen2, Pen5] Enkephalin	Opioid Receptor	Neurological Disease
[DPen2, Pen5] Enkephalin is a δ-opioid receptor selective analog of [Leu5]-Enkephalin (HY-P0288) .

HY-P1013

Deltorphin 2 [D-Ala2]-Deltorphin II	Opioid Receptor	Neurological Disease
Deltorphin 2 is a selective peptide agonist for the δ opioid receptor.

HY-P3555

D-Ala-Gly-Phe-Met-NH2	Opioid Receptor	Others
D-Ala-Gly-Phe-Met-NH2, an opioid peptide, is a potent opiate δ-receptor agonist .

HY-P1299A

UFP-101 TFA	Opioid Receptor	Neurological Disease
UFP-101 TFA is a potent, selective, and competitive antagonist of the N/OFQ peptide (NOP) receptor, with a pK_i of 10.24. UFP-101 TFA displays >3000-fold selectivity over δ, μ and κ opioid receptors. UFP-101 TFA shows antidepressant-like effect .

HY-P1467

[Met5]-Enkephalin, amide 5-Methionine-enkephalin amide	Opioid Receptor	Neurological Disease
[Met5]-Enkephalin, amide is an agonist for δ opioid receptors as well as putative ζ ζ opioid receptors.

HY-P1866

β-Endorphin, equine	Opioid Receptor	Neurological Disease
β-Endorphin, equine is an endogenous opioid peptide, which binds at high affinity to both μ/δ opioid receptors . Analgesic properties .

HY-P1332

DSLET [D-Ser2, Leu5, Thr6]-enkephalin	Opioid Receptor	Neurological Disease
DSLET ([D-Ser2, Leu5, Thr6]-enkephalin) is a highly specific agonist of the *δ-receptor. DSLET is an enkephalin-related peptide selectively bound to the δ opioid* receptor .

HY-129271

Deltorphin Deltorphin A; Dermenkephalin	Opioid Receptor	Others
Deltorphin (Deltorphin A; Dermenkephalin) is a biological active peptide. (Deltorphin A peptide was isolated from skin extracts of the South American frog, Phyllomedusa sauvagei. Deltorphin A is a potent and selective agonist for the delta-opioid receptor.)

HY-P1299

UFP-101	Opioid Receptor	Neurological Disease
UFP-101 is a potent, selective, and competitive antagonist of the NOP receptor, with a pK_i of 10.24. UFP-101 displays >3000-fold selectivity over δ, μ and κ opioid receptors. UFP-101 shows antidepressant-like effect .

HY-P1316A

Ac-RYYRWK-NH2 TFA	Opioid Receptor	Neurological Disease
Ac-RYYRWK-NH2 is a potent and selective partial agonist for the *nociceptin receptor* (NOP), [ ³H]Ac-RYYRWK-NH2 binds to rat cortical membranes ORL1 with a K_d** of 0.071 nM, but has no affinity for μ-, κ- or δ-opioid receptors .

HY-P11642A

Sialorphin TFA	Enteropeptidase Aminopeptidase Opioid Receptor ERK mTOR Androgen Receptor	Inflammation/Immunology
Sialorphin TFA is a neutral endopeptidase (NEP) and aminopeptidase N (APN) inhibitor that responds to androgen signals. Sialorphin TFA blocks the degradation of endogenous opioid peptides and interacts with μ-, δ-, κ-opioid *receptors. Sialorphin TFA regulates the ERK/mTOR* signaling pathway by inducing cell cycle arrest, enhancing ERK1/2 activity, and reducing the phosphorylation levels of mTOR, 4E-BP1, p70S6K; accordingly, Sialorphin TFA exhibits antiproliferative activity against colorectal cancer, glioma and prostate cancer cells without cytotoxicity. In addition, Sialorphin TFA also produces antinociceptive responses, regulates sexual behavior, relaxes corpus cavernosum smooth muscle, and alleviates experimental colitis. Sialorphin TFA is also a copper (II) ion-binding ligand. Sialorphin TFA has been used in mechanistic studies related to cancer, pain management and inflammatory bowel disease .

HY-P10203

*μ/κ/δ opioid* receptor agonist 1**	Opioid Receptor	Inflammation/Immunology
μ/κ/δ opioid receptor agonist 1 is a μ opioid receptor (MOR), κ opioid receptor (KOR), and δ opioid receptor (DOR) agonist. μ/κ/δ opioid receptor agonist 1 produces a strong and long-lasting analgesic effect through peripheral MOR and KOR in the tail-flick test .

HY-109166

Amdakefalin	Opioid Receptor	Neurological Disease
Amdakefalin is a μ and δ opioid receptors agonist with analgesic effects .

HY-P2199

SNF 9007	Opioid Receptor	Neurological Disease
SNF 9007 is a cholecystokinin analog. SNF 9007 induces analgesia by acting on δ-1, δ-2, and μ **opioid receptors** in the mouse brain .

HY-P2669

Boc-YPGFL(O-tBu)	Opioid Receptor	Neurological Disease
Boc-YPGFL(O-tBu) is a selective *δ opioid* receptor (DOR)** peptide antagonist .

HY-129422

Diallyl G	Opioid Receptor	Neurological Disease
Diallyl G is a **delta-opioid receptor antagonist. Diallyl G shows inhibitory effect on GTPase** .

HY-P1502F

Biocytin-β-endorphin, human	Opioid Receptor	Neurological Disease
Biocytin-β-endorphin, human is abiotinylated β-Endorphin, human (HY-P1502). β-Endorphin, human, a prominent endogenous peptide, existing in the hypophysis cerebri and hypothalamus, is an agonist of **opioid receptor*, with preferred affinity for μ-opioid* receptor and δ-opioid receptor; β-Endorphin, human exhibits antinociception activity.

HY-P1333A

Dynorphin A TFA	Opioid Receptor Apoptosis Caspase Endogenous Metabolite	Neurological Disease
Dynorphin A TFA is an endogenous opioid peptide involved in inhibitory neurotransmission in the central nervous system (CNS). Dynorphin A TFA is a highy potent *kappa opioid* receptor (KOR)** agonist, and is also an agonist for other opioid receptors, such as mu (MOR) and delta (DOR). Dynorphin A TFA can induce neuronal death, and can be used in the research of neurological disease .

HY-P3555A

D-Ala-Gly-Phe-Met-NH2 monoacetate	Opioid Receptor	Others
D-Ala-Gly-Phe-Met-NH2 monoacetate, an opioid peptide, is a potent opiate δ-receptor agonist .

HY-P1625

Daeatal Dynorphin A ethylamide (1-9)	Opioid Receptor	Neurological Disease
Daeatal (Dynorphin A ethylamide (1-9)) is an ethylamine-modified dynorphin fragment that can be used in the study of analgesia, addiction, depression, etc. Dynorphin A is an endogenous opioid peptide involved in inhibitory neurotransmission in the central nervous system (CNS). Dynorphin A is a highy potent *kappa opioid* receptor (KOR)** agonist, and is also an agonist for other opioid receptors, such as mu (MOR) and delta (DOR). Dynorphin A can induce neuronal death, and can be used in the research of neurological disease .

HY-P5892

β-Endorphin (1-27) (human)	Opioid Receptor	Neurological Disease
β-Endorphin (1-27) (human) is an *opioid* antagonist that binds μ-, δ-, and κ-opioid receptors with K_is of 5.31, 6.17, and 39.82 nM, respectively. β-Endorphin (1-27) (human) inhibits β-Endorphin (HY-P1502)-induced and etorphine-induced analgesia .

HY-P1316

Ac-RYYRWK-NH2	Opioid Receptor	Neurological Disease
Ac-RYYRWK-NH2 is a potent and selective partial agonist for the *nociceptin receptor* (NOP), [ ³H]Ac-RYYRWK-NH2 binds to rat cortical membranes ORL1 with a K_d** of 0.071 nM, but has no affinity for µ-, κ- or δ-opioid receptors .

HY-P2429

N,N-Diallyl-Tyr-Aib-Aib-Phe-Leu	Opioid Receptor	Others
N,N-Diallyl-Tyr-Aib-Aib-Phe-Leu is a compound that can antagonize the δ-opioid receptor and the action of [D-Pen2,D-Pen ] enkephalin in vivo. Its antagonistic effect can be verified by specific behavioral experiments.

HY-P1301

[Arg14,Lys15]Nociceptin	Opioid Receptor	Neurological Disease
[Arg14,Lys15]Nociceptin is a highly potent and selective *NOP receptor* (ORL1; OP4) agonist, with an EC₅₀** of 1 nM. [Arg14,Lys15]Nociceptin displays high selectivity over opioid receptors, with IC₅₀s of 0.32, 280, >10000 and 1500 nM for NOP, μ, δ and κ receptors, respectively .

HY-P1301A

[Arg14,Lys15]Nociceptin TFA	Opioid Receptor	Neurological Disease
[Arg14,Lys15]Nociceptin TFA is a highly potent and selective *NOP receptor* (ORL1; OP4) agonist, with an EC₅₀** of 1 nM. [Arg14,Lys15]Nociceptin TFA displays high selectivity over opioid receptors, with IC₅₀s of 0.32, 280, >10000 and 1500 nM for NOP, μ, δ and κ receptors, respectively .

HY-P1300

[(pF)Phe4]Nociceptin(1-13)NH2	Opioid Receptor	Neurological Disease
[(pF)Phe4]Nociceptin(1-13)NH2 is a highly potent and selective *NOP receptor* (OP4) agonist, with a pK_i of 10.68 and a pEC₅₀** of 9.31. [(pF)Phe4]Nociceptin(1-13)NH2 displays high selectivity over δ, κ, and μ opioid receptors (>3000 fold) .

HY-P1300A

[(pF)Phe4]Nociceptin(1-13)NH2 TFA	Opioid Receptor	Neurological Disease
[(pF)Phe4]Nociceptin(1-13)NH2 TFA is a highly potent and selective *NOP receptor* (OP4) agonist, with a pK_i of 10.68 and a pEC₅₀** of 9.31. [(pF)Phe4]Nociceptin(1-13)NH2 TFA displays high selectivity over δ, κ, and μ opioid receptors (>3000 fold) .

HY-P1336A

Deltorphin I TFA Deltorphin 1 TFA; Deltorphin C TFA; [D-Ala2] Deltorphin I TFA	Opioid Receptor	Neurological Disease
Deltorphin I TFA (Deltorphin 1 TFA; Deltorphin C TFA; [D-Ala2] Deltorphin I TFA) is a high-affinity, selective δ-opioid receptor agonist that targets the δ1 and δ2 opioid receptor subtypes. Deltorphin I TFA produces analgesic effects in the rat spinal cord. Deltorphin I TFA increases the pain threshold in rats. Deltorphin I TFA can be used in studies related to nociception (acute pain) .

HY-105343R

BW-180C (Standard) [D-Ala2, D-Leu5]-Enkephalin (Standard); DADLE (Standard)	Reference Standards Opioid Receptor	Neurological Disease
BW-180C (Standard) is the analytical standard of BW-180C (HY-105343). This product is intended for research and analytical applications. BW-180C ([D-Ala2, D-Leu5]-Enkephalin; DADLE) is an δ opioid receptor (DOR) agonist, which belongs to the enkephalin family. Neuroprotective agent. BW-180C reversibly inhibits cellular transcription in neurons without causing cell injury .

HY-P11642

Sialorphin	ERK Androgen Receptor Opioid Receptor Enteropeptidase mTOR Aminopeptidase	Neurological Disease Inflammation/Immunology Cancer
Sialorphin is a neutral endopeptidase (NEP) and aminopeptidase N (APN) inhibitor that responds to androgen signals. Sialorphin blocks the degradation of endogenous opioid peptides and interacts with μ-, δ-, κ-opioid *receptors. Sialorphin regulates the ERK/mTOR* signaling pathway by inducing cell cycle arrest, enhancing ERK1/2 activity, and reducing the phosphorylation levels of mTOR, 4E-BP1, p70S6K; accordingly, Sialorphin exhibits antiproliferative activity against colorectal cancer, glioma and prostate cancer cells without cytotoxicity. In addition, Sialorphin also produces antinociceptive responses, regulates sexual behavior, relaxes corpus cavernosum smooth muscle, and alleviates experimental colitis. Sialorphin is also a copper (II) ion-binding ligand. Sialorphin has been used in mechanistic studies related to cancer, pain management and inflammatory bowel disease .

Cat. No.	Product Name	Target	Research Area	Image

HY-P992012

CA1001	Opioid Receptor	Neurological Disease Cancer
CA1001 is a small-molecule ZNF74 inhibitor and a peripherally restricted κ/δ dual **opioid receptor** agonist. CA1001 exhibits potent antitumor activity both in vitro and in vivo. CA1001, in combination with immune checkpoint inhibitors, significantly enhances tumor regression. CA1001 activates peripherally restricted κ/δ dual opioid receptors and exerts analgesic effects under conditions of inflammatory pain, neuropathic pain, and mechanical hyperalgesia. CA1001 can be used in research related to melanoma, mechanical hyperalgesia, neuropathic pain, and inflammatory arthritis pain.

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-P1866A

β-Endorphin, equine TFA 1 Publications Verification	Natural Products Endogenous metabolite Source Classification	Opioid Receptor
β-Endorphin, equine TFA is an endogenous opioid peptide, which binds at high affinity to both μ/δ opioid receptors. β-Endorphin, equine TFA has analgesic properties .

HY-A0115R

Ramiprilat (Standard) HOE 498 diacid (Standard); Ramipril diacid (Standard)	Structural Classification Alkaloids Pyrrole Alkaloids Endogenous metabolite Source Classification	Drug Metabolite Reference Standards Angiotensin-converting Enzyme (ACE) Endogenous Metabolite
Alvimopan (dihydrate) (Standard) is the analytical standard of Alvimopan (dihydrate). This product is intended for research and analytical applications. Alvimopan dihydrate (ADL 8-2698 dihydrate) is a potent, selective, orally active and reversible μ-opioid receptor antagonist, with an IC50 of 1.7 nM. Alvimopan dihydrate has selectivity for μ-opioid receptor (Ki=0.47 nM) over κ- and δ-opioid receptors (Kis=100, 12 nM, respectively). Alvimopan dihydrate can be used for the research of postoperative ileus .

HY-P1866

β-Endorphin, equine	Natural Products Endogenous metabolite Source Classification	Opioid Receptor
β-Endorphin, equine is an endogenous opioid peptide, which binds at high affinity to both μ/δ opioid receptors . Analgesic properties .

HY-N12302A

(E/Z)-Scotanamine D (E/Z)-N1-Dihydrocaffeoyl, N10-caffeoyl spermidine	Structural Classification Alkaloids Other Alkaloids Anisodus tanguticus (Maxinowicz) Pascher Solanaceae Plants Source Classification	Drug Derivative
(E/Z)-Scotanamine D is a hydroxycinnamic acid amide found in the roots of Scopolia tangutica. (E/Z)-Scotanamine D is inactive against μ-, δ-, and κ-opioid receptors .

Cat. No.	Product Name	Chemical Structure

HY-76711S

Naltrexone-d4

Naltrexone-d4 is deuterium labeled Naltrexone (HY-76711). Naltrexone is an orally active, long-acting opioid receptor (opioid receptor) antagonist. Naltrexone blocks the euphoric effects of exogenous opioids and reduces alcohol craving by blocking opioid receptors (μ, κ, and δ) as well as opioid growth factor receptors. Low doses of Naltrexone are used to relieve chronic pain, treat inflammatory diseases and inhibit tumor growth, while high doses or continuous administration exert pro-inflammatory or pro-proliferative effects. Naltrexone relieves intractable pruritus caused by psoriasis, atopic dermatitis and other conditions, and its combination with Bupropion (HY-B0403) inhibits food craving, thereby reducing body weight.

HY-G0021S1

N-Desmethylclozapine-d8 hydrochloride

N-Desmethylclozapine-d₈ (hydrochloride) is the deuterium labeled N-Desmethylclozapine hydrochloride. N-Desmethylclozapine hydrochloride is a major active metabolite of the atypical antipsychotic agent Clozapine. N-Desmethylclozapine hydrochloride is a potent, allosteric and partial M1 receptors agonist (EC₅₀=115 nM) and is able to potentiate hippocampal N-methyl-d-aspartate (NMDA) receptor currents through M1 receptor activation. N-Desmethylclozapine hydrochloride is also a δ-opioid agonist .

HY-123689S1

Samidorphan-d5

Samidorphan-d5 (ALKS-33-d5) is is a deuterated compound of Samidorphan. Samidorphan is an orally active opioid system modulator that binds with high affinity to μ-opioid, κ-opioid, and δ-opioid receptors. Samidorphan is a μ-opioid receptor antagonist and a partial agonist at k-opioid and δ-opioid receptors. Samidorphan acts primarily as an opioid receptor antagonist in vivo .

HY-G0021S

N-Desmethylclozapine-d8

N-Desmethylclozapine-d₈ is the deuterium labeled N-Desmethylclozapine. N-Desmethylclozapine is a major active metabolite of the atypical antipsychotic agent Clozapine. N-Desmethylclozapine is a potent, allosteric and partial M1 receptors agonist (EC₅₀=115 nM) and is able to potentiate hippocampal N-methyl-d-aspartate (NMDA) receptor currents through M1 receptor activation. N-Desmethylclozapine is also a δ-opioid agonist .

HY-90003S

Tianeptine-d12

Tianeptine-d₁₂ is a deuterated analog of Tianeptine (HY-90003).Tianeptine is an atypical antidepressant. Tianeptine is a moderate-intensity agonist of the μ-opioid receptor (MOR), and to a lesser extent, is an agonist of the δ-opioid receptor (DOR). Tianeptine is a glutamate modulator that can enhance AMPA receptor and antagonize NMDA receptor. Tianeptine increases sensitivity of the α1 adrenergic receptor, which only manifests in chronic treatment. Tianeptine exerts neuroprotective effects under stress/inflammation-induced conditions, exhibiting anti-inflammatory and antioxidant properties. Tianeptine inhibits MMP-9 by suppressing the PI3K/Akt-mediated NF-κB pathway. Tianeptine can be used to alleviate symptoms of depression and anxiety, but does not cause sedative effects.

HY-123689S

Samidorphan-d4

Samidorphan-d4 is the deuterium labeled Samidorphan(HY-123689).Samidorphan (ALKS-33) is an orally active opioid system modulator that has a high affinity for binding with μ‐opioid, κ‐opioid, and δ‐opioid receptors. Samidorphan acts as an antagonist at μ‐opioid receptors and acts as a partial agonist at k-opioid and δ‐opioid receptors. Samidorphan primarily acts as an opioid receptor antagonist in vivo .

HY-144224S

Tianeptine-d6 hydrochloride

Tianeptine-d₆ hydrochloride is the deuterium labeled Tianeptine hydrochloride. Tianeptine hydrochloride is an atypical antidepressant. Tianeptine hydrochloride is a moderate-intensity agonist of the μ-opioid receptor (MOR), and to a lesser extent, is an agonist of the δ-opioid receptor (DOR). Tianeptine hydrochloride is a glutamate modulator that can enhance AMPA receptor and antagonize NMDA receptor. Tianeptine hydrochloride increases sensitivity of the α1 adrenergic receptor, which only manifests in chronic treatment. Tianeptine hydrochloride exerts neuroprotective effects under stress/inflammation-induced conditions, exhibiting anti-inflammatory and antioxidant properties. Tianeptine hydrochloride inhibits MMP-9 by suppressing the PI3K/Akt-mediated NF-κB pathway. Tianeptine hydrochloride can be used to alleviate symptoms of depression and anxiety, but does not cause sedative effects.

HY-13243S1

Alvimopan-d7

Alvimopan-d₇ (ADL 8-2698-d₇) is deuterium labeled Alvimopan. Alvimopan (ADL 8-2698) is a potent, selective, orally active and reversible μ-opioid receptor antagonist, with an IC₅₀ of 1.7 nM. Alvimopan has selectivity for μ-opioid receptor (K_i=0.47 nM) over κ- and δ-opioid receptors (K_is=100, 12 nM, respectively). Alvimopan can be used for the research of postoperative ileus .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

delta opioid receptors

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

NaturalProducts

Isotope-Labeled Compounds

Natural
Products